- Home
- UAMY vs CMPX Comparison
UAMY vs CMPX Comparison
Compare UAMY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- CMPX
- Stock Information
- Founded
- UAMY 1968
- CMPX 2014
- Country
- UAMY United States
- CMPX United States
- Employees
- UAMY N/A
- CMPX N/A
- Industry
- UAMY Metal Fabrications
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- CMPX Health Care
- Exchange
- UAMY Nasdaq
- CMPX Nasdaq
- Market Cap
- UAMY 251.9M
- CMPX 291.8M
- IPO Year
- UAMY N/A
- CMPX N/A
- Fundamental
- Price
- UAMY $2.74
- CMPX $2.37
- Analyst Decision
- UAMY Strong Buy
- CMPX Strong Buy
- Analyst Count
- UAMY 4
- CMPX 8
- Target Price
- UAMY $3.38
- CMPX $13.13
- AVG Volume (30 Days)
- UAMY 3.6M
- CMPX 801.4K
- Earning Date
- UAMY 08-08-2025
- CMPX 08-11-2025
- Dividend Yield
- UAMY N/A
- CMPX N/A
- EPS Growth
- UAMY N/A
- CMPX N/A
- EPS
- UAMY N/A
- CMPX N/A
- Revenue
- UAMY $18,865,900.00
- CMPX $850,000.00
- Revenue This Year
- UAMY $270.45
- CMPX N/A
- Revenue Next Year
- UAMY $104.06
- CMPX N/A
- P/E Ratio
- UAMY N/A
- CMPX N/A
- Revenue Growth
- UAMY 97.46
- CMPX N/A
- 52 Week Low
- UAMY $0.27
- CMPX $0.77
- 52 Week High
- UAMY $3.86
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- UAMY 47.10
- CMPX 53.99
- Support Level
- UAMY $2.71
- CMPX $2.17
- Resistance Level
- UAMY $3.10
- CMPX $2.49
- Average True Range (ATR)
- UAMY 0.30
- CMPX 0.18
- MACD
- UAMY -0.00
- CMPX -0.01
- Stochastic Oscillator
- UAMY 27.43
- CMPX 34.85
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.